Health Care(IN20339.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
Health Care
IN20339.HK
News
View More

CMB International Securities Reaffirms Their Buy Rating on 3SBio (TRSBF)

CMB International Securities analyst Jill Wu has reaffirmed a Buy rating on 3SBio (TRSBF) with a price target of HK$37.43, while the shares closed at HK$24.26. The analyst has an average return of 39.6% and a success rate of 59.73%. The consensus for 3SBio is a Strong Buy, with a price target consensus of HK$39.95, indicating a potential upside of 64.66%.

Tip Ranks·
SZ
159102
-0.46%
SH
513700
-0.73%
SZ
159316
-0.89%
Tip Ranks·
SZ
159102
-0.46%
SH
513700
-0.73%
SZ
159316
-0.89%

CICC Remains a Buy on Jinxin Fertility Group Ltd. (1951)

In a report released yesterday, from CICC maintained a Buy rating on Jinxin Fertility Group Ltd., with a price target of HK$3.50.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Jinxin Fertility Group Ltd. with a HK$3.50 average price target.

Tip Ranks·
HK
01951
+1.22%
Tip Ranks·
HK
01951
+1.22%

23:51 ET Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"

Akeso, Inc.announced that its drug ivonescimab has been included in FirstWord Pharma's list "The Drugs That Will Shape 2026." This list highlights 20 key drugs expected to transform the pharmaceutical industry. Ivonescimab is notable as the only drug from a Chinese innovative pharmaceutical company. The list also features other significant therapies from major pharmaceutical companies. Akeso is committed to addressing unmet clinical needs and advancing innovative medicines globally, with a focus on autoimmune and neurological disorders.

prnewswire·
SH
513700
-0.73%
SH
520880
-0.75%
SZ
159316
-0.89%
prnewswire·
SH
513700
-0.73%
SH
520880
-0.75%
SZ
159316
-0.89%

Mirxes to Raise HK$673 Million via Share Placement; Shares Fall 9%

Mirxes to Raise HK$673 Million via Share Placement; Shares Fall 9%

marketscreener·
HK
02629
-10.03%
marketscreener·
HK
02629
-10.03%

Benign Growth For Vincent Medical Holdings Limited (HKG:1612) Underpins Its Share Price

Vincent Medical Holdings Limited (HKG:1612) has a low P/E ratio of 7.3x, suggesting it may be undervalued compared to the Hong Kong market. Despite a 37% EPS growth last year, long-term growth has been weak, leading to a cautious investor outlook. The market expects limited future growth, contributing to the low P/E. Shareholders may not see significant price increases unless earnings improve. Caution is advised regarding investment decisions based on P/E ratios, as they reflect market sentiment about the company's future performance.

Simplywall·
HK
01612
+4.12%
Simplywall·
HK
01612
+4.12%
Posts
View More

$XTALPI(02228.HK) The money for meals is definitely enough.

  • 0

$XTALPI(02228.HK)  The hedging pressure from CB seems to be over? Looks like it. Yesterday @Zhou Shuren's trader made a pretty reliable call. Impressive! 👍

$XTALPI(02228.HK) went smoothly, 10,000 shares. Buy and sell for a small bite. Lunch is covered. Stay optimistic about future developments!

  • 0

$XTALPI(02228.HK)

The CB was completed yesterday.

After the trading session on January 7, 2026, Jingtai Holdings (02228) announced that it had signed a subscription agreement with underwriters such as J...

© 2026 Longbridge｜Disclaimer